Thephysiological and pathophysiologicalfunctions of PAI-1 are related to its expression by specific cell types in normaland diseasedtissues.Weanalysed the contribution of DNAmethylation to the variation in PAI-1 mRNA levels in fivecelllines.We found varying frequencies of methylation of 25 CpGsinthe -805/+152 region of the PAI-1 gene in Bowes, MCF-7 and U937 cells, while little or no methylation was detectedinHep2and HT-1080 cells. Themethylationfrequency wasinversely correlated with PAI-1 mRNA levelwithin its 20-fold range in Bowes,MCF-7,U937,and Hep2cells,while the lack of methylation in bothHep2and HT-1080 cells suggesteda notherm echanism behind the 150-fold higherlevel in HT-1080 cells thaninHep2cells.However,all cell linesexhibited ahigh frequency of methylation of 10 CpGsina CpG island at about -1800.Tr eatment with 5-aza-2'-deoxycytiKeywords PAI-1, CpG methylation,histone acetylation, cell-specific,oral carcinoma dine led up to circa a40-foldincrease in the PAI-1 mRNA level and as trong decrease in the frequency of methylation in the -805/+152 region in Bowes, MCF-7 and U937.The histone deacetylaseinhibitor trichostatinAinduced aseveral fold increase of theP AI-1 mRNA leveli nc ells with ah igh methylation frequency of the -805/+152 region.Asc ompared with matched normaltissue, three samplesoforal squamouscellcarcinomas displayedd ecreasedf requencies of methylation of the PAI-1 5' flanking region and increasedl evelso fP AI-1 mRNA.These results forthe first time implicate DNA methylation and histone acetylation in regulation of the PAI-1 gene,and indicate thatwithout proper CpG islandsin5'-flanking region,trancriptionmay be regulatedb ym ethylationo fl essd ense CpGs in the 5'-flanking region ratherthan methylation of upstreamCpG island.
Introduction
Plasminogen activator inhibitor-1 (PAI-1) regulatesthe activities of the plasminogen activatorstPA and uPA (1) , both serine proteases catalysing the conversion of the zymogen plasminogento the activep rotease plasmin. Plasmin can degrade fibrin and other extracellularproteins (2) . The relative blood plasma levels of tPAand PA I-1 determine the fibrinolytic capacity of blood (3) . In humans, ahigh plasma PA I-1 levelisarisk factor in myocardial infarction. Conditions with an increased risk of thrombotic disease, i.e., obesity,hypertension, insulin resistance, type-2dia-betes, and hypertriglyceridemia, area ssociatedw ith elevated plasma PA I-1 levels. Interestingly, inhibitorsofangiotensin converting enzyme decreaseplasma PA I-1 levels and lead to reduction in ischemic events (3) . Evidencefor adirect causal role of PA I-1 in thrombotic eventsc omes from the observation that transgenic micew ith an increased plasmaP AI-1 leveld evelop venous and arterial occlusions. There is also evidencethat PA I-1 contributestopathological remodelling of the vascularwalland arteriosclerosis (3) .uPA -catalysed plasmin generation has been implicated in the spread of cancerousd iseases,p lasmin-catalysedd egradation of basement membranes believedt oe nable cancerc ells to invade normal tissue. This idea is supported by evidencefrom modelsystems and by the observation thathigh tumourlevelsofuPA are correlated with poorprognosis in several cancers ( 2) . Surprisingly, the PA I-1 levels in tumours are higher thaninthe corresponding normal tissue, and ahigh level of PA I-1 in tumours is an even bettermarker forapoor prognosis than the uPAlevel (4) .
Thep hysiological and pathophysiological roleso fP AI-1 must be seen in relation to itscell-specificexpression, whichis againmodulated by alarge variety of hormones, cytokines,and growth factors ( 5) . In normal humans and mice, av arietyo f cellt ypes has beenr eported to express PA I-1, prominently adipocytes, hepatocytes and endothelial cells (5) .I nd iseased tissues, an increased PA I-1 expression by specificc ellt ypes mayb er elated to the pathogenesis. In the so-calledm etabolic syndrome,thereseemstobeanincreased PA I-1 production by viscerala dipose tissue, and the most important sourceo ft he elevatedP AI-1 is from stromal cells,i ncluding monocytes and smoothm uscle cells,n ot the adipocytes themselves. An elevation of the PA I-1 leveli nl ocale ndothelial cells and vascular smooth muscle cells hasbeen shown to contribute to the thrombotic complications associatedwith plaque rupture in arteriosclerotic lesions found in kidney, liverand main arteries (3, 6) . In several typesofcancers, i.e., breast, prostate,and colon cancers, it wasd emonstrated thatP AI-1 wase xpressed by several cell types, butt he predominant PA I-1 expressing cell type was the myofibroblast, ac ellt ype not present in the corresponding normal tissues (7) (8) (9) .
The possibility that epigenetic mechanisms mayc ontribute to cell-specific PA I-1 expression have caught ourinterest. One important mechanism for epigenetic regulation of gene transcription is silencing by methylation of CpG dinucleotides. CpG dinucleotidesa re underrepresented throughoutg enomes. Most CpGs(70%) in mammalian genomesr eside within repetitive elementsa nd arem ethylated, probablya sam echanism for keeping these elementstranscriptionallysilent (10) . In addition, there are so-called CpG islands, whichare definedasstretches of DNAuptoseveral kb in sizethat contain more than 6% CpG dinucleotides of the total number of nucleotides. CpG islands are usuallylocated at the 5' end of genes, and approximately 50% of all genescontain one or more promoter-associatedCpG islands. Originally, CpG islandsw ere thought to be unmethylatedinall normaltissuesregardless of transcriptionalstatus (10) . However, nowanumber of methylated CpG islands have beenidentified in normal tissues. In these cases, including the maspin gene (11) and the MCJ gene (12) ,the degree of methylation shows an inverse correlation with the transcriptionalactivity of the genesin acellortissue-specific way. In tumours, epigeneticregulation of gene expression seems to playam ajor role.A berrant hypermethylation in the silencing of tumoursuppressor genesiswell documented (13, 14) . In addition, some genesare overexpressed in cancer cells due to non-methylated CpG islands. Thesegenes include proto-oncogenes suchas c-myc (15) and bcl-2 (16) , synuclein γ in breastcarcinoma and ovarian carcinoma (17) , MAOB in humancolonic adenocarcinoma (18) , MMP-9 in lymphomas (19) , MDR1 in acutem yeloid leukemia (20) , MAGE-1 in melanomas ( 21) , and uPA in malignant breasta nd prostate tissues (22, 23) .
In ordertoinitiate an analysis of the possible contribution of CpG methylation to the variation in cellulare xpression of the PA I-1 geneinnormal and diseased tissues, we have nowanalysed the patternofmethylation of CpG dinucleotidesaround the start site of transcription of the PA I-1 genein5celllineswith apreviouslydemonstrated more than2000-fold variation in PA I-1 expression (24) .W ehavefound that methylation of 25 CpG sites within approximately 900 bp around the transcription initiation sitebut outside aproper CpG island is inverselycorrelated with the expression levelo ft he gene,a nd provide evidencet hat silencing by methylation mayact in conjunction with histone deacetylation.
Materials andmethods

Cell culture
The cell lines HT-1080 (human fibrosarcoma cells,ATCC CCL 121), Hep2 (humanlaryngeal carcinoma cells, AT CC CCL 23), MCF-7(human breast cancercells, AT CC HTB 22), and Bowes (humanm elanoma cells, AT CC CRL 9607)w ere cultured in Dulbecco's modifiedE agle's medium (DMEM). Thec elll ine U937 (humanh istiocytic lymphoma cells, AT CC CRL 1593) wasc ultured in RPMI 1640 medium. The media were supplementedwith 10% fetal bovine serum (FBS),100 IU/ml penicillin, and 100 µ g/ml streptomycin. The cells were grownat37 o Cin humidified aircontaining 5% CO 2 .
5-aza-2'-deoxycytidineand trichostatinAtreatment of cells Cells (0.5×10 6 )w ere seeded in 10 cm tissue culturedishesin 10 ml of standard medium. Foradose-response study,5-aza-2'-deoxycytidine (5-aza-CdR)(Sigma)was added at day1(at~50% confluency), with final concentrations of 0.5, 1, 2, and 5 µ M. The medium waschangedevery day. At day4,cells were harvested foranalysis. Time coursestudieswere performed by incubating cells with 5 µ M5-aza-CdRfor 1, 2, or 3days, respectively(for U937cells, 1 µ M5-aza-CdRwas used).Insome cases, trichostatin A(TSA) (Sigma) wasadded at day3atafinalconcentration of 0.5 µ M (25) .
The harvested cells were separated in twoparts, one for preparation of DNA(DNeasy Tissue Kit, Qiagen) and onefor preparation of cytoplasmic RNA( RNeasyM ini Kit, Qiagen).O ncolumn DNase digestion by RNA-freeD Nase I( Qiagen) was performed during the RNApurification procedure.
Oralsquamous cell carcinomasamples and matched normal tissues
Laser microdissected,u nfixed frozens amples fromt hreeo ral squamouscellcarcinomasand matchedadjacent normal tissues from the same patient were obtainedf rom Odense University Hospital, Denmark as previouslyd escribed (26) .All three patients were men, aged 61,65, and 69 years,and the tumours were located at floor, tongue and inferior alveolar ridge,respectively.
In silicoanalysis forCpG islands
The genomic PA I-1 sequence (GeneBank Accession No. NM_000602)w as screened forCpG islands, by the use of two CpG plotp rogrammes( http://www.ebi.ac.uk/emboss/cpgplot/) and (http://www.ucsf.edu/urogene/methprimer/index1.html), withthe following parameters: 100 bp length, 50% G+Cand 0.6 observed/expected ratio, where "observed" is the observed number of CpG sites and "expected" equals (numbero fC s* number of Gs)/windowlength.
Methylation-specific PCR(MS-PCR)
Genomic DNAwas treated with sodium bisulfite as previously described (26) . The primer sequencesusedfor methylation-specific PCR(MS-PCR)analysis of the PA I-1 5'-flanking region are listedi nT able 1. PCR reaction mixtures (25 µ l) contained1 0 pmol/µ lofeach primer, covering +10 to +129, 0.2 mM of each dNTP,1xPCR buffer and 1unit of HotStarTaqDNA polymerase (Qiagen), 0.2 mM cresol red, 12% (w/v) sucrose, and 50-100 ng of bisulfite-treated DNA (26) . Reactions were startedwith initial denaturation at 95°C for 10 min, followedby35cyclesat95°C for 30 s, the appropriate annealing temperaturefor 30 sand 72°C for 30 s. The annealing temperatures for the unmethylated and methylated reactions were 55°C and 57°C, respectively.T he PCRproductswere resolvedon2%agarosegels. CpGenome universally methylatedDNA (Chemicon InternationalInc., California, USA) serveda st he methylated positivec ontrol. This DNAisenzymaticallymethylatedhuman male genomic DNA.
Bisulfitesequencing
Bisulfite sequencing wasperformed as described elsewhere (17, 18) . PCR amplification wasperformed in 25 µ lofreaction mixturec ontaining 100 ng bisulfite-treated DNA, 10 pmol/ µ lo f each primer(Table1), 0.2mMofeach dNTP,1xPCR buffer and 1u nit of HotStarTaqD NA polymerase (Qiagen). Fora mplification of SqProx, a431 bp sequence in the proximal region of the PA I-1 genefrom -278 to +152, the reaction wasstarted with initiald enaturation at 95°C for 10 min, followedb y3 5c yclesa t 95°C for 1min, 55°C for 1min and 72°C for 2min. Foramplification of SqDistal, a537 bp sequence in the distal region from -805 to -268, the reaction wasstarted with initialdenaturation at 95°C for 10 min, followedby40cyclesat95°C for 1.5 min, 57°C for 1m in and 72°C for 2.5m in. Fora mplification of the upstream CpG island,the reaction wasperformed by using the programme for MSPd escribed above;t he annealing temperature was5 7°C.A mplifiedD NA wass ubclonedi nto the vector pCR2.1byusing aOne Shot Electroporation TOPO TA cloning kit (Invitrogen) and sequenced using the Dynamic  ET terminator cyclesequencing kit(Amersham PharmaciaBiot) and a 373A ABI sequencer(Applied Biosystems).F or analysis of the upstream CpG island,the PCRproduct wasgel purified beforeit wassubcloned(Gel Extraction Kit,Qiagen).Ten positive clones were analysed for each sample. The frequencyo f methylated CpG sites(FMS) wascalculated as (number of methylatedCpG sites/ 25 CpG sites)x100%. The frequencyo f total methylated CpGs( FTM) wasc alculated as (number of methylatedC pGs /number of totallydetected CpGs)x100%.
Quantitative real-time RT PCR
Reverse transcription reaction wasperformed with 2 µ gDNAfree RNA, usingFirst-strand cDNASynthesis Kit (Amersham). Quantitative real-time RT PCR wasperformed according to the instruction of the manufacturer.The primer sequencesare shown in Table1.The amplification reaction for quantitative real-time RT PCR wascarried outinafinal volume of 25 µ l, containing 2x Brilliant MultiplexM asterM ix (Stratagene). Thec omparative CT (threshold cycle) method described in the manufacturer's protocol wasu sedt oq uantitate the relative PA I-1 mRNAe xpression level, comparing treated samples to concordantu ntreatedcontrols. Thermal conditions were as follows:95°C for 10 minutes to activate the DNAp olymerase,t hen 40 cycles at 95°C for 30 s, 62°C for 30 s, and 72°C for 30 s. Amplification wasperformed on aMx4000 ® MultiplexQuantitative PCR System( Stratagene). Theg lyceraldehyde3 -phosphate dehydrogenase(GAPDH)gene mRNAwas amplifiedasaninternal control to normalise the data of the PA I-1 mRNAlevel.All PA I-1 mRNA levels were expressed relative to the PA I-1 mRNAinthe cell line HT-1080, whichh as ah igh PA I-1 expression and wasrun as a positivecontrol in each reaction.
Statisticalanalysis
The effect of 5-aza-CdRo nm ethylation wasa nalysed with x 2 test. All analyses fore ffectso f5 -aza-CdRa nd TSA on PA I-1 mRNAb yq uantitative real-time RT PCR were performed at leastthreetimesand presentedthe mean±SD.Paired-t test was performed for comparing the effects of 5-aza-CdR and TSA.
Primers
Primer 
Results
CpGsites in the PAI-1 gene
The human PA I-1 geneislocalised on chromosome7q22.1 (27) . We screened the genomic PA I-1 sequence (GeneBank Accession No.NM_000602) forCpG islands. Initially, we screened an interval of 1kbupstreamand 1kbdownstreamfrom the transcription initiation site.Inthe region from -805 to +152, spanning the PA I-1 5'-flanking region and the first exon, and containing binding sites for anumber of transcription factorsimplicated in regulation of PA I-1 genetranscription (5, 28)( Fig. 1) , we found 25 CpG dinucleotides, whichwewill refer to aCpG #1 to #25, beginning from the 3´end. However, no typical CpG island was identified. Althoughsmallerand less CpG-rich than properCpG islands, twoshortsequences were seen to have arelativelyhigh density of CpGs. Thus, there were five CpGs(#24 to #20) from -679 to -639, whichhas been referred to as aGC-rich sequence previously ( 29) , and five CpGs( #5 to #1) from +91t o+ 121. Whenweextendedour searchto2kbupstreamand 2kbdown-streamfrom the transcription initiation site,one small CpG island wasfound,covering -1897to-1766 (132 bp) and containing 7CpG sites. We willrefer to it as the upstream CpG island. By screening this sequenceand its flanking sequencesmanually, we identifiedatotal of 10 CpGs between-1936 and -1721 (Fig.  1 ). There were no CpG islandsupto2kbdownstreamofthe transcription startsite.
Cell lines with different levels of PA I-1 expression
To analysethe impact of CpG methylation on the expression of the PA I-1 gene, we chose five celllines, HT-1080,Hep2,U937, MCF-7 and Bowes, whichwere previously shown to have highly variable levels of PA I-1 expression, as evidenced by ELISA measurements of PA I-1 protein levels in their conditionedmedia (24) . Thev ariable levelofP AI-1 expression wasconfirmed by analysis of PA I-1 mRNAexpression. Realtime RT-PCR results showedv ariations in PA I-1 mRNAl evelss imilart ot he previouslyreported variationsinP AI-1 protein levels in the five cell lines. Compared with HT-1080,t he relative PA I-1 mRNAe xpression levels of Hep2, U937, MCF-7 and Boweswere around 1/150, 1/600, 1/1800 and 1/3300, respectively (Fig. 2) .
Analysis of CpGmethylation in the cell lines by MSP analysis and bisulfitesequencing
To investigatewhetherthe PA I-1 expression levelwas correlated with the methylation status of CpG dinucleotideslocated at 5'region of the PA I-1 gene, methylation analysis wasperformed by both MSPa nd bisulfite sequencing. By MSP analysis with primers covering +10 to +129, CpG methylation wasf ound in Bowes, MCF-7,and U937. The signal obtained with the primers for methylatedDNA wasstronger thanthe signal obtained with the primersfor unmethylated DNAinBowes and MCF-7 cells, while the opposite pattern wasseen in U937, indicating thatthe frequencyofmethylation wasmuch higher in Bowesand MCF-7 than in U937 cells.H owever,n om ethylation waso bservedi n Hep2 and HT-1080cells (Fig. 3) .The methylation status wasin- verselycorrelated with the PA I-1 mRNAexpression levelamong the different cell lines (Fig. 2) . Bisulfite sequencing wasp erformed fort he region from -805 to +152, containing 25 CpG dinucleotides, and for the region from -1936 to -1721, containing 10 CpGs (Fig. 1) . Two pairsofprimers were used for amplifying the 958 bp sequence from -805 to +152, one covering CpG #1 to #11, whichwill be referred to as the proximalregion, and anothercovering CpG #12 to #25,which will be referred to as the distalregion. Theanalysis showeddifferent frequencies of methylation in the different cell lines (Fig. 4) . Methylation wasobservedat25, 18, and 12 of the 25 CpG sites in Bowes, MCF-7 and U937 cells, respectively, corresponding to afrequencyofmethylatedCpG sites (FMS)of 100%, 72% and 48%, and afrequencyoftotal methylated CpGs (FTM) of 66%, 44% and 20%, respectively ( Table 2) .Inparticular, CpGs#1to#4, #7, #13 and #15 were methylatedinall investigated clones fromBowes cells, while CpG #1, #2, #7, and #15 were methylatedi na ll investigated clones fromM CF-7c ells. Methylation at CpG sites#1to#5, #20 and #21, included in two clusters with relativehigh CpG density,was observed in allthree celllines. CpG methylation wasonlyfound at twoCpG sites (#1 and #20) in 2o f1 0d ifferent clones in Hep2 cells, while no methylation wasobservedinHT-1080 cells.
Surprisingly, methylation wasfound in all five celllinesatall CpG sitesinthe upstreamCpG island at -1936 to -1721 (Fig. 4) . Especially, the frequencyofmethylation in HT-1080 and Hep2 cells, with high and moderate PA I-1 expression, wasnot significantly different from that in Bowes, MCF-7,and U937 cells,with lowP AI-1 expression.
Effect of 5-aza-CdR and TSA treatment on PA I-1 expressionlevels in the cell lines
We analysed the effect of 5-aza-CdR treatment on the methylation pattern of the PA I-1 genea nd on the PA I-1 mRNAe xpression in U937, MCF-7 and Bowescells. By MSP analysis, we observedat ime-a nd dose-dependent alteration in the methylation pattern, consisting in adecreased intensity of the band obtainedwith the primers for methylatedDNA,but an increased intensity with the primersfor unmethylated DNA (Fig. 5) . By bisulfite sequencing, 5-aza-CdR treatment wasfound to result in demethylation of most of CpGs in the -805 to +152 region in all threecelllines(Table2, Fig. 4) .InBowes,5-aza-CdRtreatment resultedincomplete demethylation of CpGs #6 -#11, #16, #17, #19, #24, and #25, while incomplete demethylation wasfound at the other CpGs, except forCpG #12, the methylation of which wasnot affectedbythe treatment. In MCF-7 cells,therewas no change in the number of methylatedCpG sites, butthe frequency of methylation at each sitedecreased,and twoofthe analysed clones lacked methylation at CpGs#1-#11. In U937 cells,the treatment resulted in complete demethylation at CpG sites #2, #3, #4, #13, #14, #18, and #21, and incomplete demethylation at other CpG sites, except #15, the methylation of whichwas notaffected.Thus, the frequencyofmethylatedCpG sites (FMS)and the frequencyoftotal methylated CpGs (FTM) decreasedinall three celll ines, and there wasadecrease in the frequencyo f methylation at most CpG sites, especially in the proximalregion. Totally, by comparing the frequencyo ft otal methylated CpGs (FTM) betweenuntreatedand 5-aza-CdR treatedcells, asignificant decreasewas found, from 43.6%to15.5% when datafrom all cellswere pooled (p<0.001)( Table 2) .
Representativee xperiments on the dose-dependencea nd time-course of 5-aza-CdR effect on PA I-1 mRNAlevel,asanalysedr eal time RT-PCR were showni nF igure5 .W eo bserved 1.5, 2, 9and 17 fold increase of the relative PA I-1 mRNAlevel by 3days'treatment of MCF-7 cells with 5-aza-CdR in 0.5,1.0, 2.0, and 5.0 µ Mconcentrations,respectively; and 6-,15-and 33-fold increase by treatment of Bowescells with 5.0 µ M5-aza-CdRfor 1, 2, and 3days, respectively (Fig. 5) . Treatment of 5-aza-CdR for3daysalso caused a5-foldincrease of the PA I-1 mRNAlevel in U937 cells, buthad no significant effect on the PA I-1 mRNA levelinHep2 cells (Fig. 6) .
It has becomeclear thatdeacetylation of histonesisalso involved in the gene silencing and mayplayarole associated with that of DNAmethylation (30) . We therefore alsoe xamined the potential role of histone acetylation in the regulation of the PA I-1 genee xpression, using treatment with TSA, ahistonedeacety- lase inhibitor,w ith or without simultaneous treatment with 5-aza-CdR (Fig. 6 ).W ef ound that TSA treatment caused a6 -and 8-fold increase of the PA I-1 mRNAl evel in MCF-7 and Bowes, respectively, whichhad ahigh frequencyofmethylation of the -805to+152 region, butnooronlyamodest increase in cells with al ower frequency of methylation, U937 and Hep2. These resultsi ndicated that the histone acetylation status was also implicated in the control of transcription of the PA I-1 gene, particularlyincells with ahigh levelofCpG methylation of the PA I-1 5'-flanking region.
PAI-1 gene 5'-flankingregionmethylation and mRNA expressioninoral carcinomas and matchednormal tissues
In order to evaluate whether variation in methylation frequency is also inverselyc orrelated with PA I-1 expression in intact tissues, we analysed 3samples of oral squamous cellcarcinomas and matchednormal tissues from the same patients. These 3par-ticularpatients were chosen for analysis becausethe PA I-1 levels in the tumourtissue were 22-, 13-, and 12-foldhigherthan in the matchednormal tissues (Fig. 7) . CpG methylation of the PA I-1 gene5 '-flanking region wasf ound in all threetumours and all threenormal tissues, butthe frequencyofmethylatedCpG sites (FMS)was lowerinthe tumour samples than in the corresponding normal tissue samples, 16% vs 40%, 4% vs 24%, and 8%vs 24%, respectively (Fig. 7) . Thus, therewas an inverse correlation between methylation and expression also in these samples from tumours and intact tissues.
Discussion
The present results implicate for the first time CpG methylation in the regulation of PA I-1 genet ranscription. No CpG island could be identifiedinthe region from -805 to +152 relative to the transcription initiation site.N eitherc ould anyC pG island be identified up to 2000 bp downstream of the transcription initiation site, butasmall island wasf ound at about 1800 bp upstream. We observedthat the degree of methylation of 25 CpG dinucleotidesinthe PA I-1 -805 to +152 region wasinverselycorrelated with the levelofP AI-1 mRNA in five different cell lines. Treatment of the cells with 5-aza-CdR resultedindemethylation of the CpGsi nt he region and in increased levels of PA I-1 mRNA. In contrast, the methylation status of 10 CpGsinthe upstreamC pG island wasn ot correlated with the PA I-1 mRNA levels in the five celll ines. We therefore believe thatw eh ave stronga rguments, although no proof,w hich supportt he notion that methylation of the CpGs in the 5'-flanking region and the first exon, butnot of the farupstreamCpG island,iscausally involved in regulation of transcription of the PA I-1 gene. Proof willr equired emonstration that in vitro methylated5 '-flanking region drivestranscription from areporter genelessefficiently thannon-methylated 5'-flanking region. 
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However, it is also clear thatothermechanisms for transcriptionalregulation areequallyasimportant as the -805to+152 region lackedmethylation in both Hep2 and HT-1080cells, which nevertheless had around 150-fold different levels of PA I-1 mRNA. Inspecting the PA I-1 mRNAlevelsinthe different cell lines in the absence and presenceof5-aza-CdR, onemay concludethat variationsinCpG methylation areresponsible for differences in expression of one to twoo rders of magnitude,l ike thatbetween Bowesand Hep2 cells,while other,positivelyacting factorsa re important for the very high expression by HT-1080cells.
AlthoughD NA methylation in CpG islands is believedt o playa ni mportant rolei nr egulation of gene expression, it has beens uggestedt hat methylation of CpG islands localised at exonic sites with ag reat distance from the 5'-flanking region cannota ffect transcription (12,3 1) . Results from methylation studies of the ABO gene (26) and the hTERT (32)gene also indicated thataclosed istanceo faC pG island from transcription initiation sitewas necessary for generegulation by methylation of the CpG island. Ourpresentresults are in agreement with such ah ypothesis since we found thatm ethylation of the upstream CpG island wasn ot related to the PA I-1 genee xpression. The small size of this CpG island mayalso contribute to its lack of importance, similarly to the suggestion about CpG island methylationofthe p16 promoter and exon 2region (33) . In the absence of CpG islandsclose to the 5'-end of genes, methylation of less densely spaced CpGsinthe promoter region maybemore relevant to transcriptional regulation than CpG islands. It has previouslyb een suggested thatn on-CpG island promoterso f variousg enes undergo transcriptionala ctivation by demethylation of specific sequencesinatissue-specific fashion (34) .One recent reportshowedthat DNAmethylation also plays arole in control of IL-4 (interleukin-4) gene expression whichexhibited onlyrare CpG sitesinthe promoter region: site-specific methylation of 5CpG sites within approximate 800 bp promoterregion wasfound more important than methylation of CpGs more than -900 bp away from the transcriptionali nitiation site ( 35) . The p53 promoter does not contain aC pG island either,b ut alterations in CpG methylation in the p53 promoterhavebeen found to be site-specific and to vary withthe stage of carcinogenesis. A critical single CpG site could work in initiation of de novo methylation, and progressives preading of methylation wasa ssociatedw ith transcriptionali nactivation of the p53 gene (36) . One mayconsider whether an analogous situation exists with the PA I-1 gene, butwecould not find such acritical CpG site in present study.AsnotypicalCpG island wasfound in the PA I-1 promoter, the relatived ensity of CpG sitesm ay be important for regulating transcription. We found twoCpG clusterscontaining relative higher density of CpGs, i.e., five CpGs(#24 to #20) from -679 to -639 and five CpGs(#5 to #1) from +91to+121. In fact, we found amore frequent methylation of CpGs #5 to #1 than of the other CpGs in Bowes, MCF-7,a nd U937 cells,m aking it possible thatm ethylation of the PA I-1 gene5 '-flanking region spreads from an initiation site to adjacent sites (12) .
One possiblemechanism by whichCpG methylation maysilencetranscriptionalactivity is by directlypreventing the binding of transcription factorst ot heir DNAb indings ites ( 10) .To function in this way, it is necessary thatthe methylated CpG dinucleotides lie in or neart he cis-acting regulatorye lements. Methylation maybetargeted to these particularregions through direct interaction with sequence-specific DNA-binding proteins, whichf urthermore mayr egulate cell-specific gene expression (10, 37) . Previous studies of the PA I-1 gene5'-flanking region showed thatthe region up to -805 contains anumber of sequencesinvolved in recognition of transcription factorsand in regulation of transcriptional activity of the PA I-1 geneb yh ormones, cytokines,and growth factors (Fig. 1) . As aresult, transcriptionalcontrol of the PA I-1 geneisapivotalmechanism in determining tissue and plasma PA I-1 content (38) . In present study, the potentiallymethylatedCpGs were mostlyfound outside the regulatorys equences identifieds of ar.P otentially methylatedCpGs were seen in the twoEboxes overlapping with HRE-5 and HRE-4 (CACGTG, CpG #24a nd #19), in HRE-3 and HRE-2 (CCACGTTT,C pG #16 and ACACGTAC,C pG #11), as well as the VLDLRE (GGAGTCAGCCGTGTAT-CATCG,CpG #23 and #22) (10) .However,all these sitesshowed arelativelylow methylation frequency, and it is therefore notat the present stagep ossible to makec onclusions concerning a possible direct regulatorycorrelation betweenCpG methylation and transcriptional factor binding in the PA I-1 gene.
An alternativep ossibilityf or am echanism by whichC pG methylation mayaffect genetranscription is binding of methyl binding proteins to methylatedCpGs, whichagain attract histone deacetylases.Deacetylation of histone favours an inactive chromatin configuration (39) .W efound that an inhibitor of histone deacetylase, TSA, could increase the levelo fP AI-1 mRNA in cells with extensive methylation of the PA I-1 5'-flanking region, i.e., Bowesand MCF-7 cells,while therewas little or no effect in cells with less extensive methylation, i.e., U937 and Hep2cells. Likewise,t herew as little or no effect of TSAi n5 -aza-CdR treated Bowesand MCF-7 cells.Our observation with TSA is in agreement with the concept thatmethylatedCpGs attract histone deacetylases whichmediatethe gene silencing, as TSA does not affect CpG methylation (30) .
Therefore,the conclusion is that variable methylation of the PA I-1 gene5'-flanking region in different cell lines, rather than methylation of an upstream CpG island,isinverselycorrelated with variable transcription of the PA I-1 gene. Thus,methylation of PA I-1 5'-flanking region mayb ea nother exampleo ft issue specificpatternsofmethylation, followingthe maspin and MCJ genes (11, 12) . However, different methylation of the 5'-flanking region could not explain the different PA I-1 mRNAl evelsi n Hep2 and HT-1080cells, indicating thatother, transcriptionalor post-transcriptional regulatorymechanisms are equally important in determining the PA I-1 mRNAlevels. Our present findings areparticularlyrelevant for the elucidation of the types of abnormaltranscriptionalregulation whichleads to overexpression of components of the plasminogena ctivation systemi nc ancers. Our preliminary results on oral squamous cellcarcinomasindicate that variation in CpG methylation of the PA I-1 gene5'-flanking region maywellcontribute to the higher expression of PA I-1 in tumours thaninthe corresponding normal tissue. In anumber of recent papers, the role of CpG methylation for expression of uPAinbreast and prostate tumours have beenreported,the focus being the expression of uPAb ythe malignant cells themselves (22, 23) . However, it is important to realise thatb oth uPAa nd PA I-1 in tumours are expressed by av arietyo fc ellt ypes. In breast tumours, the predominant uPAand PA I-1 expressing cell type areinfact stromalcells (7, 40) , while in oral cancers, the predominant PA I-1 expressing cell type arethe malignant cells themselves (41).Ane lucidation of the genetic,e pigenetic and other regulatorym echanisms determining the expression of PA I-1 in different cell typesintumours is therefore aparticularly interesting challenge.
